Portfolio Companies

Current
Former
IPOs
All

Actelion Holding Ltd

Actelion is a Swiss biopharmaceutical company focusing on pulmonary arterial hypertension (PAH). The company listed on the Swiss Stock Exchange in 2000 and was later acquired by Johnson & Johnson in 2016.

Adcendo ApS

Adcendo ApS

www.adcendo.com

Adcendo is developing novel antibody-drug conjugates (ADCs) for treatment of cancers. The company is building an ADC pipeline against uPARAP and other ideally suited ADC cancer targets.

Aerocrine AB

Aerocrine is a medical technology company that develops and commercializes unique, easy-to-use and tailored products for the measurement of nitric oxide (NO) as an inflammatory marker for patients with inflammatory disorders, such as asthma. Aerocrine listed on the Nasdaq OMX Stockholm stock exchange in 2007 and was later acquired by Circassia Pharmaceuticals in 2015.

Aerogen Inc

Aerogen operated as a specialty pharmaceutical company that developed, manufactured and commercialized pulmonary drug delivery products. The company was acquired by Nektar in 2005.

Affibody AB

Affibody is a Swedish biotech company focused on developing biopharmaceuticals based on its unique proprietary technology platforms Affibody® molecules and Albumod™.

Alba Therapeutics Corp

Alba’s platform is based on the discovery of zonulin, a protein that regulates cell barriers throughout the body. It enables development of novel therapeutics for a variety of inflammatory and immune mediated diseases, such as Celiac disease (gluten intolerance) and diabetes.

Algeta ASA

Algeta was a Norwegian cancer drug maker that developed injectable radioactive oncology treatments. The company listed on the Oslo Stock Exchange in 2007 and was acquired by Bayer in 2014.

Altimmune, Inc. (Immune Targeting Systems Ltd)

www.altimmune.com

Altimmune is a clinical stage biotechnology company developing next-generation vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary vaccine delivery platforms, Altimmune can rapidly design vaccines against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer.

Apoxis SA

Apoxis was a Swiss company that focused on the discovery and development of therapeutics targeting cell death, inflammation and angiogenesis for the treatment of cancer and autoimmune disease. The company merged with TopoTarget A/S.

Aprea Therapeutics

www.aprea.com

Aprea Therapeutuics is a US/Swedish oncology company developing a unique compound restoring mutant defective tumor suppressor protein p53 for a wide range of oncology indications. The lead program APR-246 is in clinical trials to treat ovarian cancer. Aprea is listed on Nasdaq.

Ariceum Therapeutics

www.ariceum-therapeutics.com

Ariceum Therapeutics is a clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers such as small cell lung cancer (SCLC) and neuroblastoma.

Aro Biotherapeutics

www.arobiotx.com

Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Arpida AG

Arpida was a Swiss biopharmaceutical company focused on the discovery and development of novel proprietary antibiotics to treat severe bacterial infections. The company listed on the Swiss Stock Exchange in 2005.

AstaCarotene AB

AstaCarotene was a Swedish company that focused on extraction of astaxanthin from cultures of the microalgae Haematococcus Pluvialis.

BioCrine AB

BioCrine was a Swedish company formed around the scientific platform on -cell physiology and pato-physiology in relation to diabetes type I and II, which originated from a research group at the Karolinska Institute and Karolinska Hospital. The company merged with BioStratum, Inc.

BioFactor Therapeutics AB

BioFactor was a Swedish company that focused on the development of novel pharmaceutical approaches for the treatment of gastrointestinal disorder. The company merged with Melacure Therapeutics AB.

Biolipox AB

Biolipox was a Swedish company formed around the discovery of the metabolic pathway for arachidonic acid, which originated from a research group at the Karolinska Institute and Karolinska Hospital. The company merged with Orexo AB.

Bionaut Pharmaceuticals Inc.

Bionaut was a drug discovery company which focused on small molecule drug candidates.

Biotage AB (Pyrosequencing AB)

Biotage focuses on genetic analysis and medical chemistry. Pyrosequencing listed on the Stockholm Stock Exchange in 2000 and later merged with Biotage.

Bonesupport AB

www.bonesupport.com

BONESUPPORT is active in the field of injectable bone substitutes for orthopedic trauma and focuses on bone infection, instrument augmentation related to orthopedic surgery and spinal applications. CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe.

BrainCool AB (BeneChill Inc.)

www.braincool.se

BrainCool AB is developing products within therapeutic hypothermia to reduce risk of injury after acute ischemic events, such as cardiac arrest, stroke, and traumatic brain injury. BrainCool acquired all assets and rights from BeneChill Inc. for shares. BrainCool is listed on Aktietorget.

Carisma Therapeutics

www.carismatx.com

Carisma Therapeutics is developing novel cell therapies by re-engineering macrophages expressing CAR, a tumor recognition receptor, enabling the immune system to attack solid tumors. The pipeline is composed of several programs, with the potential lead program being for HER-2 expressing tumors.

Carmeda AB

Carmeda is a medical coating company, which engages in the development, manufacturing, and marketing of biocompatible coatings for medical devices. The company was acquired by Gore in 2005.

Cebix AB (Creative Peptides AB)

Cebix focused on the development of a disease-modifying replacement peptide for the treatment of complications associated with diabetes.

CePep AB

CePep was a Swedish company formed around the scientific platform of cell penetrating peptides exerting effects on intracellular signal transduction pathways. The company merged with Orexo AB.

Cerenis Therapeutics Holding SA

www.cerenis.com

Cerenis is focusing on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. The company’s lead program is a recombinant and optimized HDL. Cerenis listed on Euronext Paris in 2015.

ChemoCentryx Inc.

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The company listed on Nasdaq in 2012.

Clinical Data care in Lund AB

Clinical Data Care in Lund AB was a Swedish company that provided clinical trial services. The company merged with Clinitrac AB. After the merger, the combined entity was acquired by the larger clinical research organisation Trial Form Support AB.

Clinitrac AB

Clinitrac was a Swedish company with a technology focused on registration of patient data in clinical trials. The company merged with Clinical Data Care in Lund AB. After the merger, the combined entity was acquired by the larger clinical research organisation Trial Form Support AB.

CLL Pharma S.A. (Synt:em)

Synt:em S.A. was a French company focused on computer-assisted rational drug design. The company merged with CLL Pharma, a pharmaceutical laboratory that is developing generic drugs and galenical formulations.

Conpharm AB

Conpharm provided therapeutics based on natural and synthetic substances from the plant Podophyllum emodi for treatment of inflammatory diseases.

CoreValve SA

CoreValve develops trans-catheter aortic valve implantation platforms. The company was acquired by Medtronic in 2009.

Cytos Biotechnology AG

Cytos is a biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform. The company listed on the Swiss Stock Exchange in 2002 and was combined with Kuros Biosurgery to create Kuros Biosciences in 2015.

Doctrin

Doctrin

www.doctrin.com

Doctrin, founded in 2016, aims to facilitate healthcare providers to digitize the patient journey. The company has developed a cloud based B2B system for healthcare providers collecting medical history from patients before medical consultation. In addition, Doctrin provides digital solutions for doctors’ consultations to increase patient involvement and facilitate doctor-patient communication. The development will continue with AI based solutions.

Dynavax Technologies

Dynavax is a clinical-stage biopharmaceutical company, which uses Toll-like Receptor (TLR) biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company listed on Nasdaq in 2004.

Elsa Science AB

www.elsa.science/en/

Elsa Science is a digital healthtech company aiming at improving care for chronic patients, starting with Rheumatic Arthritis (RA), where in particular the U.S. faces a shortage of American rheumatologists. The Company was founded based on the research from professors Lars Klareskog (an authority in the rheumatology field) and Lars Alfredsson. Elsa provides a platform which holds a number of functionalities such as a digital companion, remote patient monitoring, optimal personalized treatment and prognostic models.

Esperion Therapeutics Inc

Esperion Therapeutics was a biopharmaceutical company primarily focused on the research and development of therapies to regulate high-density lipoprotein cholesterol, or HDL-C. The company listed on Nasdaq IN 2000.

EsyTech AB

EsyTech was a Swedish medical technology company focused on the research, development, manufacturing and commercialization of instrumentation and related products intended for chemical analysis or other types of measurements. The company merged with Pyrosequencing.

Ferrokin Biosciences Inc.

Ferrokin developed an iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was acquired by Shire in 2012.

Five Prime Therapeutics Inc.

FivePrime is discovering and developing innovative antibody and protein therapeutics using its comprehensive discovery platform. The company listed on Nasdaq IN 2013.

Fusion Pharmaceuticals Inc.

www.fusionpharma.com

Fusion Pharmaceuticals is a clinical stage radiopharmaceutical start-up, focusing on targeted alpha therapy to treat metastatic solid tumors

Genizon BioSciences, Inc. (Global Genomics)

Global Genomics was a Swedish company with a patented technology for rapid and accurate global expression analysis of genes. The company merged with Genizon BioSciences.

GenSight Biologics S.A.

GenSight Biologics S.A.

GenSight is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight’s first program is a gene therapy for Leber Hereditary Optic Neuropathy, a rare genetic disorder, in which patients lack an enzyme necessary for energy production leading to gradual vision loss and blindness. The company has received orphan drug designation in EU and US for this program. Gensight is listed on Euronext Paris.

Glionova AB

Glionova Therapeutics is a biopharmaceutical company focused on developing new therapies for cancer. The Company’s lead candidate is a first-in-class, orally available oncolytic small molecule, currently being developed as a potentially disease modifying therapy for glioblastoma by targeting specific vulnerabilities in tumor cells.

Gyros AB

Gyros manufactures laboratory instruments, consumables, kits and software to maximize laboratory productivity by miniaturizing and automating immunoassays at nanoliter-scale.

HelloBetter

www.hellobetter.de/en/

HelloBetter is a German company developing digital therapeutics for people suffering from mental health disorders.

Hemab Therapeutics

www.hemab.com

Hemab Therapeutics is a biotech company focused on developing novel treatments for rare severe bleeding disorders. Hemab is building a pipeline of bi-specific antibodies targeting various underserved bleeding disorders.

Hybrigenics S.A.

Hybrigenics is a bio-pharmaceutical company focused on research and development of new targets and therapies against proliferative diseases. The company listed on Euronext Paris in 2007.

IDEA AG

IDEA’s proprietary technology focuses on enabling non-invasive delivery of drugs through the skin.

InCarda Therapeutics Inc.

InCarda Therapeutics Inc.

www.incardatherapeutics.com

InCarda Therapeutics is a clinical stage biotechnology company developing an inhaled therapy to treat paroxysmal atrial fibrillation, a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

Inion Oy

Inion was a Finnish medical device company that developed non-metallic biodegradable implants to improve surgical solutions for reconstructive surgery, orthopedics, sports medicine and dental surgery. The company listed on the London Stock Exchange in 2004.

Jerini AG

Jerini was an orphan drug company focused on novel peptide-based drugs, with lead product Firazyr targeting Hereditary Angioedema. The company listed on the Frankfurt Stock Exchange in 2005 and was acquired by Shire in 2008.

Karo Pharma (Karo Bio)

Karo Pharma is a listed pharmaceutical company that develops and markets drugs for unmet medical needs to pharmacies, grocery stores and directly to hospitals. The company started as a biotech-company with several candidates in pre-clinical phase based on research on nuclear receptors as target proteins. Today the company has added several approved pharmaceutical products to complement its R&D Pipeline.

Lica Pharmaceuticals A/S

Lica Pharmaceuticals provided novel and unique compounds for the treatment of parasitic and bacterial diseases.

LTB4 Sweden AB

LTB4 is developing a naturally occurring molecule stimulating the innate immunity system to target diseases such as infections and cancer.

Lumavita AG

Lumavita was a Swiss specialty pharmaceutical company that focused on the development and marketing of new drugs to address infections for women’s health.

Mahzi Therapeutics

www.mahzi.com

Mahzi focuses on developing therapeutics for underserved rare genetic neurodevelopmental disorders. The goal is to choose the best therapeutic approach for each individual disease and to advance that potential medicine as rapidly as possible.

Maxim Pharmaceuticals, Inc.

Maxim was a US-based listed biopharmaceutical company developing cancer and vaccine products.

Medicarb AB

Medicarb developed biocompatible coating technologies and merged with Carmeda, which was acquired by Gore in 2005.

Melacure Therapeutics AB

Melacure was a Swedish company that focused on melanocortin receptor biology and pharmacology.

Millicore AB

Millicore developed MEMS-based (Micro-Electro-Mechanical Systems) intelligent disposable surgical products to increase the quality and decrease the cost of care. Millicore was acquired by Medela in 2010.

MIPS AB

www.mipscorp.com

MIPS is a global leader in helmet safety with a patented technology designed to reduce rotational forces to the brain during impact. Helmets integrated with MIPS’ safety solutions are marketed globally by major helmet brands in sport segments such as bicycle, snow, motorcycle and equestrian. Mips is listed on Nasdaq Stockholm Exchange.

Modus Therapeutics

www.modustx.com

Modus Therapeutics, located in Stockholm, Sweden, is developing a novel treatment targeting the vaso-occlusive crises associated with sickle-cell disease (SCD). SCD is a devastating rare genetic red blood cell disorder. It is characterized by abnormal hemoglobin resulting in anemia and sickling of the red blood cells that obstruct the blood flow.

Neoventa Medical AB

Neoventa is a provider of innovative fetal monitoring solutions and services that improve obstetric care.

NephroGenex (BioStratum, Inc.)

www.nephrogenx.com

NephroGenex Inc. is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease. Pyridorin was acquired for shares from BioStratum, Inc. NephroGenex listed on Nasdaq in 2014.

Neuro3D SA

Neuro3D developed innovative treatments for psychiatric disorders such as schizophrenia, depression and anxiety. The company was acquired by Evotec in 2007.

Newron Pharmaceuticals SpA (NeuroNova AB)

Newron is a biopharmaceutical company with focus on therapies for the Central Nervous System in indications such as Parkinson’s disease, neuropathic low back pain and other cognitive disorders. The company acquired NeuroNova AB in 2012 and is listed on the Swiss Stock Exchange.

Nexstim Oy

www.nexstim.com

Nexstim is focused on commercializing a brain scanning technology enabling pre-surgical mapping, neurodiagnostics, as well as neurotherapy applications such as stroke rehabilitation. Nexstim listed on Nasdaq OMX Stockholm and Helsinki stock exchanges in 2014.

NicOx S.A.

NicOx S.A.

NicOx is a French ophthalmic company which listed on Euronext Paris in 1999.

Nobex Corp.

Nobex focused on the modification of peptide drugs for improved clinical performance and delivery into the body.

Nordic Nanovector AS

www.nordicnanovector.no

Nordic Nanovector AS is a clinical stage biotechnology company developing radiopharmaceuticals for hematological cancer patients. Nordic Nanovector’s lead product Betalutin is currently being investigated in Non-Hodgkin’s lymphoma (NHL) and has received orphan drug designation in EU and US. Nordic Nanovector listed on the Oslo Stock Exchange in 2015

Nordic Vision Clinics AS (Optivy AB)

Nordic Vision Clinics AS is a chain of laser eye surgery clinics in Sweden under the name Globen Ögonklinik.

Nucleonics, Inc.

Nucleonics was a US biotechnology company focused on the development of novel RNA-interference based therapeutics for viral diseases (such as hepatitis B, hepatitis C and HIV) as well as other diseases

Odyssey Thera Inc.

Odyssey Thera’s proprietary platform technology, protein-fragment complementation assay (PCA), is designed to optimize the predictability and speed of drug discovery and development to find treatments for cancer and other diseases.

Oncopeptides AB

Oncopeptides AB

www.oncopeptides.com

Oncopeptides is a clinical stage pharmaceutical company developing oncology therapies centered on peptidase targeting. Ygalo (Melflufen), Oncopeptides lead drug compound, is a peptidase potentiated therapy that will shortly commence a pivotal Phase 3 clinical study approved under the US Food and Drug Administration’s Special Protocol Assessment for relapsed and relapsed-refractory multiple myeloma. Orphan Drug Designation for Ygalo (Melflufen) in the treatment of Multiple Myeloma has been granted by EMA and FDA. Oncopeptides is listed on Nasdaq Stockholm Exchange.

Oncorena

Oncorena

www.oncorena.com

Oncorena is a Swedish pharma company developing orellanine, – a unique, highly organ-specific and potentially curative therapy for patients with metastatic renal cancer.

Onxeo S.A. (TopoTarget A/S)

www.onxeo.com

Onxeo is a clinical stage biopharmaceutical company focused on orphan oncology, created by the merger between Topotarget and Onxeo. Its lead drug candidate, Beleodaq, has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy and has received orphan drug designation in EU and US for Peripheral T-Cell Lymphoma. Onxeo is listed on Euronext Paris and Nasdaq OMX Copenhagen stock exchanges.

OraPharma Inc.

OraPharma Inc. offered oral healthcare for the treatment of periodontal disease. The company was listed on Nasdaq up to its acquisition by Johnson & Johnson.

Orchid BioSciences Inc.

Orchid BioSciences focused on the development and commercialization of genetic diversity technologies, products and services. The company listed on Nasdaq in 2000 and later changed its name to Orchid Cellmark. Orchid Cellmark was acquired by Laboratory Corporation of America in 2011.

Orexo AB

www.orexo.com

Orexo is a specialty pharmaceutical company developing improved treatments using its proprietary drug delivery technology. The company has a portfolio of revenue generating EU and US approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo listed on the Nasdaq OMX Stockholm Stock Exchange in 2005.

OxThera AB

OxThera is a spin-out company from Q-Med AB and is developing products using its cell- and enzyme-based proprietary technologies for metabolic disorders based on excess oxalate, a primary risk for kidney stone formation.

Personal Chemistry AB

Personal Chemistry was a Swedish company that had developed a technology by which microwaves used to catalyze chemical reactions. The company merged with Pyrosequencing.

Pharmexa A/S

Pharmexa A/S was a Danish vaccine company which listed on the Copenhagen Stock Exchange in 2000 and was later merged with Affitech AS.

Pharmion Corp.

Pharmion focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients. The company listed on Nasdaq in 2003 and was later acquired by Celgene.

Precirix

www.precirix.com

Precirix is a spin-off company of Vrije Universiteit Brussel, developing novel radiopharmaceuticals to treat cancer. The proprietary technology combines small single domain antibody fragments, called nanobodies, with radioactive isotopes to treat cancer.

Pretzel Therapeutics

www.pretzeltx.com

Pretzel Therapeutics is a biotechnology company developing therapeutics for mitochondrial diseases. The company takes aim at genetic drivers of mitochondrial dysfunction relevant for a wide range of diseases.

Priothera Ltd.

www.priothera.com

Priothera is a start-up biotech company looking to develop KRP-203 for hematological disorders. Recent long-term data from a proof-of-concept study in patients with hematological cancers treated with stem cell transplantation (HSCT) indicates that KRP-203 may be an attractive novel treatment for addressing unmet medical need for these patients.

ProCorde AG

ProCorde was a German cardiovascular-focused company that merged with Trigen Ltd., a UK-based company developing drugs for the treatment of cardiovascular diseases with a focus on thrombosis.

Prolifix Ltd.

Prolifix was a UK-based drug discovery-company focusing its activities on developing new pharmaceuticals which inhibit the cell cycle. The company merged with TopoTarget A/S.

Prothelia Inc.

Prothelia Inc.

www.prothelia.com

Prothelia is a US based private biotech company founded in 2007. Prothelia’s lead program is a novel protein therapy for the treatment of congenital muscular dystrophy type 1A, a rare disease affecting approximately 4,000 patients.

PTC Therapeutics Inc.

PTC focuses on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology. The company listed on NASDAQ in 2013.

Pulmonx Corp.

www.pulmonx.com

Pulmonx is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company has developed products to deliver effective endoscopic lung volume reduction (ELVR) to patients with emphysema-induced hyperinflation. Pulmonx products are sold in Europe, Asia, and in other countries worldwide.

Q-Med AB

Q-Med marketed a portfolio of products developed using the company’s proprietary technology based on stabilized hyaluronic acid. The company listed on the Stockholm Stock Exchange in 1999 and was later acquired by Swiss pharmaceutical company Galderma.

Rainier Therapeutics Inc.

Rainier Therapeutics was developing a monoclonal antibody for the treatment of genetic orphan and oncology diseases. Development programs included achondroplasia, a rare skeletal condition, and metastatic bladder cancer patients who already have failed first-line chemotherapy. Rainier was acquired by Fusion Pharmaceuticals in 2021.

Renovis Inc.

Renovis developed drugs to treat neurological diseases and disorders. The company listed on Nasdaq in 2004 and was acquired by Evotec in 2008.

Renovo Ltd.

Renovo developed drugs to prevent scars and accelerate wound healing in the skin. The company listed on the London Stock Exchange in 2006.

Resistentia Pharmaceuticals AB

Resistentia was a Swedish research-based pharmaceutical company focusing on the development of vaccines aimed at preventing allergy.

ReVENT Medical Inc. (ReVent Medical International B.V.)

www.reventmedical.com

ReVENT Medical has developed the ReVENT Sleep Apnea System, which comprises minimally invasive, biocompatible implants targeting tongue based Obstructive Sleep Apnea (OSA). The device is CE marked for the European market.

RSPR Pharma AB

www.rsprpharma.com

RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.

Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.

Sequenom Inc. (Eurona AB / Gemini Genomics plc)

Eurona AB was a clinical genetics company with a proprietary genotyping technology. Eurona was merged into Gemini Genomics, which listed on NASDAQ in 2000 and later was merged with Sequenom.

Sopherion Therapeutics Inc.

Sopherion was a biopharmaceutical company which acquired, discovered, and developed targeted anti-cancer agents. All assets have been acquired by Zoticon.

SpineVision S.A.

www.spinevision.com

SpineVision is a medical technology company developing a comprehensive range of spinal implants. The spinal implants are used for treatment of spinal disorders, including deformities, degenerative disc disease, tumors and traumas. The company has several products on the market and distributes them throughout the world.

Spruce Biosciences

www.sprucebiosciences.com

Spruce Biosciences is a private US based clinical-stage biotech company developing novel therapies for rare endocrine disorders. Spruce’s lead product candidate, Tildacerfont (SPR001), has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease.

SynOx Therapeutics Ltd

SynOx Therapeutics Ltd

www.synoxtherapeutics.com

Synox is a spin-out from UK based oncology company Celleron, based in Ireland and jointly formed by Celleron, the investors and Roche. The company is developing Emactuzumab, an antibody licensed from Roche, targeting a rare soft tissue tumor, TGCT, often affecting joints in the lower extremity.

Targovax AS (Oncos)

www.targovax.com

In 2015, Targovax acquired Oncos in an all-stock transaction, creating a new Nordic leader in immuno-oncology. The new combined company Targovax is targeting two complementary approaches to cancer immunotherapy: a cancer vaccine platform developed for patients with RAS-mutated cancers and an immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Targovax is listed on Oslo Børs.

Technolas Perfect Vision GmbH

Technolas Perfect Vision was a leading ophthalmology laser company, formed through a joint venture between Bausch + Lomb, and 20/10 Perfect Vision AG. The company was acquired by Bausch + Lomb in 2013.

Tengion Inc

Tengion focused on regenerative medicine and the development of its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. The company listed on NASDAQ in 2010.

Tisbury Pharmaceutical

www.tisburypharmaceuticals.com

Tisbury Pharmaceutical Inc (Tisbury Pharmaceuticals BV). is a pharmaceutical company developing a first-in-class drug to treat glaucoma. Its primary development target is patients with open angle glaucoma and ocular hypertension patients.

Tribune Therapeutics AB

tribunetx.com

Tribune Therapeutics is a pre-clinical stage biopharmaceutical company co-founded by HealthCap. Tribune is developing a fusion protein to treat patients with fibrotic disease.

Trigen Ltd.

Trigen was a UK-based biotechnology company that developed drugs for the treatment of cardiovascular diseases with a focus on thrombosis. The company merged with ProCorde, an early-stage German cardiovascular company.

Trimb Healthcare AB

www.trimb.se

Trimb is focused on the development and sales and marketing of prescription free pharmaceuticals (OTC) and personal care products. The Company has its own go-to-market organization in Northern Europe and in addition, select products are sold internationally through distributors.

Tripep AB

Tripep focused on the development of new types of therapies using its protein polymer inhibitor platform technology, with an initial focus on HIV. The company listed on the Stockholm Stock Exchange in 2000.

Ultragenyx Pharmaceuticals Inc.

Ultragenyx focuses on developing therapeutics for rare (orphan) diseases. Following its formation, the company rapidly built a diverse portfolio of orphan drug product candidates and listed on NASDAQ in 2014.

Ultrazonix Holding AB

Ultrazonix was a Swedish medical technology company that focused on the development of high-intensive focused ultrasound products primarily for the treatment of low back pain. The company merged with BoneSupport AB.

Vägakuten AB

Vägakuten was a Swedish company with a strategy to establish highly accessible roadside medical stations.

Vicore Pharma

www.vicorepharma.com

Vicore Pharma is a Swedish company with a broad portfolio of projects for the treatment of different forms of interstitial lung diseases. In 2018, listed company Vicore merged with HealthCap startup INIM Pharma, to form a company with the potential to become leading in the field of rare lung diseases.

Vir A/S

Vir focused on the development of a surface plasmon resonance technology.

Visual Bioinformatics AB

Visual Bioinformatics was a Swedish company that developed novel and innovative software solutions for storage, retrieval and interpretation of data generated through functional genomics technologies. The company was merged with Affibody AB.

Vivet Therapeutics

www.vivet-therapeutics.com

Vivet Therapeutics is a French biotech company developing gene therapy for rare liver diseases with high unmet medical need, including Wilson Disease, primary familiar intrahepatic cholestasis type 2 (PFIC2), and citrullinemia type 1 (CTLN1). The company’s development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes.

Wilnor AB

Wilnor was a Swedish company focused on the development and marketing of software for industrial and clinical laboratories.

Wilson Therapeutics AB

www.wilsontherapeutics.com

Wilson Therapeutics was an orphan biopharmaceutical company, based in Stockholm, Sweden, that developed novel therapies for patients with Wilson Disease. Wilson was listed on Nasdaq Stockholm Exchange and was acquired by Alexion in 2018.

XCounter AB

XCounter developed a digital x-ray imaging technology enabling single photon detection and determination of a photon’s individual energy. The company listed on the London Stock Exchange’s AIM market in 2006.

Xenerate AB

Xenerate was a Swedish company developing a technology to enable artificial vascular prosthesis, such as stents and grafts, to be covered by endothelial cells.

Xeris Biopharma Holdings, Inc (Strongbridge)

www.xerispharma.com

Strongbridge Biopharma was a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. The main therapeutic focus was on rare neuromuscular and endocrine diseases such as Primary Periodic Paralysis and Cushing’s syndrome. The company listed on NASDAQ in 2015 and was acquired for shares by Xeris Pharmaceuticals in 2021.

York Pharma Plc (Charterhouse)

Charterhouse Therapeutics was an early stage drug discovery company with focus on research and development of anti-viral drugs based on a naturally occurring molecular structure, the cyclopentenone ring of certain prostaglandins. The company merged with York Pharma Plc.